trending Market Intelligence /marketintelligence/en/news-insights/trending/tRy5X60U7G4tgxRlOlJQ9w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Maruho acquires license to Solasia treatment, to invest in Japanese drugmaker

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Maruho acquires license to Solasia treatment, to invest in Japanese drugmaker

Japan's Maruho Co.Ltd. secured the rights to commercialize Solasia Pharma K.K.'s SP-04 in the country.

Maruho will pay ¥1 billion to Solasia, also based in Japan, as upfront consideration and has agreed to pay up to a further ¥18 billion once the therapy meets certain development and marketing milestones. SP-04, also known as PledOx, is still undergoing clinical studies and Solasia will exclusively supply the drug to Maruho after its development.

SP-04 is being studied as a treatment for chemotherapy induced nerve damage.

Maruho is also acquiring 9.7% of Solasia by purchasing 11,324,000 common shares of the company via a third-party allotment. Maruho will buy the shares at ¥151 each.

Solasia plans to use the net proceeds for in-licensing and development of a new drug called SP-05.

Maruho is a privately held company that focuses on therapies for skin disorders caused by cancer treatment.

As of Dec. 9, US$1 was equivalent to 108.60 Japanese yen.